Cargando…
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
Beta (B.1.351)–variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19–related death were 1.24-fold (1.11–1.39), 1.49-fold (1.13–1.97), an...
Autores principales: | Abu-Raddad, Laith J, Chemaitelly, Hiam, Ayoub, Houssein H, Yassine, Hadi M, Benslimane, Fatiha M, Al Khatib, Hebah A, Tang, Patrick, Hasan, Mohammad R, Coyle, Peter, AlMukdad, Sawsan, Al Kanaani, Zaina, Al Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F, Nasrallah, Gheyath K, Al Kuwari, Mohamed Ghaith, Butt, Adeel A, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H, Al Khal, Abdullatif, Bertollini, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402694/ https://www.ncbi.nlm.nih.gov/pubmed/34657152 http://dx.doi.org/10.1093/cid/ciab909 |
Ejemplares similares
-
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2022) -
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2021) -
SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
por: Seedat, Shaheen, et al.
Publicado: (2021) -
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022) -
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)